U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents [Reuters (UK)]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Reuters
U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents | Reuters 2 Min Read (Reuters) - A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, giving Amneal Pharmaceuticals Inc a boost in its effort to launch a generic version of the medicine. The U.S. Court of Appeals for the Federal Circuit affirmed a series of rulings in favor of Amneal that the Jazz patents described obvious ideas. Shares of Jazz fell 2.5 percent to $175 in morning trading, while Amneal was up 1 percent to $18.50. Jazz said in a statement it was disappointed in the ruling but that it only involves a “subset” of its patents covering Xyrem. “We remain confident in the strength of our remaining patent estate for Xyrem,” Jazz said. Amneal did not immediately respond to requests for comment. Amneal had asked an administrative court run by the U.S. Patent and Trademark Office to cancel the patents in hopes of bringing a generic version of X
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024PR Newswire
- Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024PR Newswire
- Acute Lymphocytic Leukemia (ALL) Pipeline Landscape Report 2024: Comprehensive Insights About 250+ Companies and 250+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off [Seeking Alpha]Seeking Alpha
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $180.00 price target on the stock.MarketBeat
JAZZ
Earnings
- 2/28/24 - Beat
JAZZ
Sec Filings
- 4/9/24 - Form 4
- 3/8/24 - Form 4
- 3/7/24 - Form 4
- JAZZ's page on the SEC website